KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bionano Genomics (BNGO) EBITDA Margin (2017 - 2025)

Bionano Genomics (BNGO) has disclosed EBITDA Margin for 9 consecutive years, with 242.41% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin fell 59705.0% to 242.41% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 19.39% through Dec 2025, up 5702.0% year-over-year, with the annual reading at 10.27% for FY2025, 5704.0% up from the prior year.
  • EBITDA Margin hit 242.41% in Q4 2025 for Bionano Genomics, up from 115.9% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 839.46% in Q4 2024 to a low of 1214.98% in Q3 2023.
  • Historically, EBITDA Margin has averaged 328.9% across 5 years, with a median of 435.75% in 2021.
  • Biggest five-year swings in EBITDA Margin: crashed -76977bps in 2023 and later skyrocketed 107221bps in 2024.
  • Year by year, EBITDA Margin stood at 456.73% in 2021, then decreased by 0bps to 456.81% in 2022, then skyrocketed by 49bps to 232.75% in 2023, then soared by 461bps to 839.46% in 2024, then tumbled by -71bps to 242.41% in 2025.
  • Business Quant data shows EBITDA Margin for BNGO at 242.41% in Q4 2025, 115.9% in Q3 2025, and 115.85% in Q2 2025.